Yervoy (ipilimumab) – a CTLA‑4 checkpoint inhibitor
| Metric | Typical values for Yervoy | Typical values for other checkpoint inhibitors (PD‑1/PD‑L1) | Key take‑aways |
|--------|---------------------------|-------------------------------------------------------------|----------------|
| Overall response rate (ORR) | 15–25 % in metastatic melanoma (single‑agent) | 20–30 % with nivolumab or pembrolizumab (single‑agent) | Similar or slightly lower ORR, but responses tend to be more durable. |
| Median overall survival (mOS) | 10–15 months (historical melanoma trials) | 20–30 months with PD‑1 agents | PD‑1 agents give better median OS; ipilimumab is still useful when combined with PD‑1 therapy. |
| Progression‑free survival (PFS) | 4–6 months | 6–12 months | PD‑1 agents usually confer longer PFS. |
| Durability of response | 40–60 % of responders remain progression‑free 3 years | 30–40 % of responders remain progression‑free 3 years | Ipilimumab responses are often long‑lasting despite lower initial ORR. |
| Grade ≥ 3 adverse events | 30–40 % (immune‑related colitis, hepatitis, hypophysitis) | 10–20 % (mostly endocrine, skin, colitis) | Ipilimumab has higher toxicity. |
| Combination with PD‑1 inhibitors (e.g., nivolumab + ipilimumab) | mOS ~ 15–20 months in melanoma; 28‑month OS ~ 50 % | Nivolumab monotherapy ~ 20–30 months OS; Pembrolizumab monotherapy ~ 20–30 months OS | The combo provides the best survival in melanoma but also the highest toxicity (≈ 40 % grade ≥ 3). |
What the numbers mean
1. Monotherapy – In the classic phase 3 melanoma trials (e.g., Rota et al. 2015, NEJM), ipilimumab achieved an ORR of ~17 % and median OS of 10–15 months. PD‑1 agents like nivolumab and pembrolizumab showed ORRs of ~20–30 % and median OS of 20–30 months.
Result: PD‑1 monotherapy is usually preferred as first‑line treatment because it offers higher response rates and better overall survival with less toxicity.
2. Combination therapy – The CheckMate‑067 trial (nivolumab + ipilimumab) demonstrated a median OS of 20 months and a 28‑month OS rate of 51 % versus 34 % for nivolumab alone. The combination improves survival over either drug alone but raises the risk of grade ≥ 3 immune toxicities from ~10 % (nivolumab) to ~40 % (combo).
Result: Combination is often reserved for patients who can tolerate higher toxicity, such as those with aggressive disease or high tumor burden.
3. Other indications
- Renal cell carcinoma (RCC): Ipilimumab + nivolumab achieved median OS of 34 months vs 23 months for nivolumab alone (CheckMate‑214).
- Non‑small‑cell lung cancer (NSCLC): Ipilimumab + nivolumab had a median OS of 14.4 months vs 12.7 months for nivolumab alone (CheckMate‑227).
In both cancers, the combination again improves survival modestly but increases adverse events.
4. Durability – Among patients who achieve a complete response (CR), those on ipilimumab often remain progression‑free for years, a phenomenon less common with PD‑1 monotherapy. This makes ipilimumab attractive when long‑term control is desired and the patient can manage higher toxicity.
Practical considerations
| Factor | Yervoy (ipilimumab) | PD‑1/PD‑L1 agents |
|--------|----------------------|--------------------|
| When to consider | High‑risk metastatic melanoma, RCC, or NSCLC; patients who can tolerate significant immune toxicity; when durable, long‑lasting responses are critical. | First‑line monotherapy in many cancers (melanoma, NSCLC, RCC, head‑and‑neck); when a milder toxicity profile is preferred. |
| Monitoring | Watch for hypophysitis, severe colitis, hepatitis, dermatitis; need endocrine labs. | Monitor thyroid, liver enzymes, skin; usually less frequent endocrine issues. |
| Cost & access | Generally similar cost to other biologics but can be high; insurance coverage often limited to specific indications or combination regimens. | Similar cost; many insurance plans cover PD‑1 agents as first‑line; combinations may be more expensive. |
Bottom line
- Efficacy: Ipilimumab has a lower ORR and median OS as monotherapy compared with PD‑1 inhibitors, but its responses are more durable for those who do respond.
- Combination: Adding ipilimumab to a PD‑1 blocker improves overall survival across several cancers, yet it also substantially increases toxicity.
- Clinical choice: Most clinicians now reserve ipilimumab for combination regimens or as a second‑line option when durable control is sought or when patients cannot tolerate PD‑1 monotherapy.
If you’re evaluating a specific cancer type or patient scenario, let me know—I can give more tailored information.